CN105732630B - 一种cbz-缬更昔洛韦的制备方法 - Google Patents
一种cbz-缬更昔洛韦的制备方法 Download PDFInfo
- Publication number
- CN105732630B CN105732630B CN201610246694.6A CN201610246694A CN105732630B CN 105732630 B CN105732630 B CN 105732630B CN 201610246694 A CN201610246694 A CN 201610246694A CN 105732630 B CN105732630 B CN 105732630B
- Authority
- CN
- China
- Prior art keywords
- cbz
- monoesters
- valganciclovir
- filtrate
- filter cake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002149 valganciclovir Drugs 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000706 filtrate Substances 0.000 claims abstract description 56
- 239000012065 filter cake Substances 0.000 claims abstract description 48
- 238000003825 pressing Methods 0.000 claims abstract description 41
- 239000012043 crude product Substances 0.000 claims abstract description 37
- 229960002963 ganciclovir Drugs 0.000 claims abstract description 37
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000002253 acid Substances 0.000 claims abstract description 30
- 150000002148 esters Chemical class 0.000 claims abstract description 30
- 239000007787 solid Substances 0.000 claims abstract description 28
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000001816 cooling Methods 0.000 claims abstract description 11
- 239000004474 valine Substances 0.000 claims abstract description 11
- 238000003756 stirring Methods 0.000 claims abstract description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims abstract description 9
- 238000010992 reflux Methods 0.000 claims abstract description 9
- 230000000630 rising effect Effects 0.000 claims abstract description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 9
- 239000004744 fabric Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims 1
- 229910001948 sodium oxide Inorganic materials 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 10
- 239000000376 reactant Substances 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 abstract description 8
- 239000002699 waste material Substances 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 229960004295 valine Drugs 0.000 description 7
- 239000002994 raw material Substances 0.000 description 6
- ZORWARFPXPVJLW-MTFPJWTKSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropyl] (2s)-2-amino-3-methylbutanoate;hydron;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 ZORWARFPXPVJLW-MTFPJWTKSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960004983 valganciclovir hydrochloride Drugs 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 239000003344 environmental pollutant Substances 0.000 description 3
- 231100000719 pollutant Toxicity 0.000 description 3
- -1 valyl ester Chemical class 0.000 description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610246694.6A CN105732630B (zh) | 2016-04-20 | 2016-04-20 | 一种cbz-缬更昔洛韦的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610246694.6A CN105732630B (zh) | 2016-04-20 | 2016-04-20 | 一种cbz-缬更昔洛韦的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105732630A CN105732630A (zh) | 2016-07-06 |
CN105732630B true CN105732630B (zh) | 2018-11-30 |
Family
ID=56255609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610246694.6A Active CN105732630B (zh) | 2016-04-20 | 2016-04-20 | 一种cbz-缬更昔洛韦的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105732630B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108218871A (zh) * | 2018-03-13 | 2018-06-29 | 上药康丽(常州)药业有限公司 | 一种cbz-缬更昔洛韦的精制方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840890A (en) * | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
CN102070635A (zh) * | 2009-11-19 | 2011-05-25 | 浙江车头制药有限公司 | 一种更昔洛韦缬氨酸酯衍生物的制备方法 |
CN102702199A (zh) * | 2012-06-13 | 2012-10-03 | 湖北葛店人福药业有限责任公司 | 一种制备更昔洛韦的方法 |
-
2016
- 2016-04-20 CN CN201610246694.6A patent/CN105732630B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840890A (en) * | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
CN102070635A (zh) * | 2009-11-19 | 2011-05-25 | 浙江车头制药有限公司 | 一种更昔洛韦缬氨酸酯衍生物的制备方法 |
CN102702199A (zh) * | 2012-06-13 | 2012-10-03 | 湖北葛店人福药业有限责任公司 | 一种制备更昔洛韦的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105732630A (zh) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109053838A (zh) | 制备β-烟酰胺单核苷酸或β-烟酰胺核糖的方法 | |
CN104844499A (zh) | 一锅法制备尼达尼布的合成方法 | |
CN103360425A (zh) | 替诺福韦酯及其富马酸盐的合成方法 | |
CN104761552B (zh) | 一种更昔洛韦缩合物异构体的处理方法 | |
CN105732630B (zh) | 一种cbz-缬更昔洛韦的制备方法 | |
US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
CN104774194A (zh) | 氘代的丙型肝炎病毒抑制剂 | |
CN101597288B (zh) | 2-氨基酰-β-咔啉-3-甲酰色氨酸苄酯及其制备方法和应用 | |
CN105315332A (zh) | CIPPC-AA-OBzl,其制备,纳米结构,活性和应用 | |
CN101607926B (zh) | 从十二烷基硫酸钠去除硫酸钠和氯化钠的方法 | |
WO2006110810A2 (en) | Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine | |
CN104387421B (zh) | 阿德福韦酯一水合物及其制备方法 | |
CN105693722B (zh) | 一种cbz-缬更昔洛韦的制备方法 | |
CN110041320B (zh) | 一种阿齐沙坦的结晶的制备方法 | |
CN105693723B (zh) | 一种cbz-缬更昔洛韦单酯的制备方法 | |
CN108137644B (zh) | 一种具有抗肿瘤作用的化合物及其制备方法和应用 | |
CN105693724B (zh) | 一种cbz‑缬更昔洛韦的制备方法 | |
CN105837710A (zh) | 药用聚乙烯醇的制备方法及其药用聚乙烯醇与应用 | |
CN108863831A (zh) | 一种注射用盐酸丙帕他莫及其制备方法 | |
CN101597290A (zh) | β-咔啉-3-甲酰色氨酰氨基酸苄酯及其制备方法和应用 | |
CN108250183A (zh) | 一种高纯度的托匹司他的制备方法 | |
CN103086956B (zh) | 一种丁酸氯维地平中间体的纯化方法 | |
CN106916149A (zh) | 一种制备苏沃雷生的方法 | |
CN101646685B (zh) | 合成ib-meca的方法 | |
CN106916184B (zh) | 一种替诺福韦二吡呋酯的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Preparation Method of CBZ Valganciclovir Granted publication date: 20181130 Pledgee: China Postal Savings Bank Limited by Share Ltd. Anqing branch Pledgor: ANHUI HAIKANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980000631 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: 246000 No.21, Huancheng West Road, Daguan District, Anqing City, Anhui Province Patentee after: Anhui Haikang Pharmaceutical Co.,Ltd. Country or region after: China Address before: 246000 No.21, Huancheng West Road, Daguan District, Anqing City, Anhui Province Patentee before: ANHUI HAIKANG PHARMACEUTICAL Co.,Ltd. Country or region before: China |